Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II infant study of combined meningococcal ABCWY vaccines
2021-001367-24Phase 2Suspended
- Sponsor
- GSK
- Start
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of MenABCWY-1Gen vaccine, meningococcal group B vaccine and meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine in meningococcal disease (6 arms), sponsored by GSK. Primary endpoint: Percentage of participants with solicited administration site events. Started Jul 2021; status: suspended.
02
Drugs
MenABCWY-1Gen vaccinemeningococcal group B vaccinemeningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2021-001367-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001367-24.